{"id":"phase-2-clozapine","safety":{"commonSideEffects":[{"rate":"0.5-1%","effect":"Agranulocytosis"},{"rate":"40-50%","effect":"Sedation"},{"rate":"30-40%","effect":"Weight gain"},{"rate":"10-20%","effect":"Orthostatic hypotension"},{"rate":"20-30%","effect":"Tachycardia"},{"rate":"1-2%","effect":"Seizures"},{"rate":"<1%","effect":"Myocarditis"},{"rate":"30-40%","effect":"Hypersalivation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clozapine antagonizes dopamine D2 and serotonin 5-HT2A receptors, reducing psychotic symptoms. It also has activity at multiple other receptors including muscarinic, histaminergic, and adrenergic receptors, which contribute to both its therapeutic effects and side effect profile. Its unique pharmacology makes it effective in treatment-resistant schizophrenia where other antipsychotics have failed.","oneSentence":"Clozapine is an atypical antipsychotic that blocks dopamine D2 receptors and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:43.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant schizophrenia"},{"name":"Reduction of suicidal behavior in schizophrenia or schizoaffective disorder"}]},"trialDetails":[{"nctId":"NCT06456983","phase":"NA","title":"Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial","status":"RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2025-02-14","conditions":"Schizophrenia, Treatment Resistant Schizophrenia","enrollment":140},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT03263533","phase":"EARLY_PHASE1","title":"HDAC Inhibitor Augmentation to Clozapine","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2017-04","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT04849026","phase":"PHASE1","title":"Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18","status":"COMPLETED","sponsor":"Whanin Pharmaceutical Company","startDate":"2021-01-15","conditions":"Schizophrenia","enrollment":33},{"nctId":"NCT03094429","phase":"PHASE2, PHASE3","title":"An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults","status":"RECRUITING","sponsor":"SyneuRx International (Taiwan) Corp","startDate":"2017-03-29","conditions":"Refractory Schizophrenia","enrollment":287},{"nctId":"NCT01248195","phase":"PHASE4","title":"Optimization of Treatment and Management of Schizophrenia in Europe","status":"COMPLETED","sponsor":"Rene Kahn","startDate":"2011-05","conditions":"Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder","enrollment":479},{"nctId":"NCT00169091","phase":"PHASE4","title":"Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia","status":"TERMINATED","sponsor":"Harvard Medical School (HMS and HSDM)","startDate":"1996-03","conditions":"Schizophrenia","enrollment":32},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT00000372","phase":"PHASE3","title":"Glycine and D-Cycloserine in Schizophrenia","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"1998-03","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00534573","phase":"PHASE3","title":"Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation","status":"COMPLETED","sponsor":"Beersheva Mental Health Center","startDate":"2008-11","conditions":"Clozapine-induced Hypersalivation","enrollment":54},{"nctId":"NCT01105481","phase":"PHASE4","title":"Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2006-05","conditions":"Treatment-resistant Schizophrenia","enrollment":273},{"nctId":"NCT00757978","phase":"PHASE4","title":"Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2006-01","conditions":"Schizophrenia","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Phase 2: Clozapine","genericName":"Phase 2: Clozapine","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clozapine is an atypical antipsychotic that blocks dopamine D2 receptors and serotonin 5-HT2A receptors in the brain. Used for Treatment-resistant schizophrenia, Reduction of suicidal behavior in schizophrenia or schizoaffective disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}